Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products
Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...
CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA
China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration...
Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...
Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease
China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval...
Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of...
Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...
Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer
Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that...
Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease
Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from...
Hanx Biopharmaceuticals Gains NMPA Approval for HX044 Clinical Trials
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clinical trial approval from...
Likang Life Sciences Gains FDA Approval for LK101 Clinical Trials
Beijing-based cell therapy developer Likang Life Sciences announced that it has received approval from the...
CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, has received approval from the State-owned...
EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Akeso Completes Enrollment for Global Phase III Trial of Ivonescimab in Lung Cancer
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the global...
Bayer Files for EMA Approval of Kerendia for Heart Failure
Bayer AG (FRA: BAYN) announced that it has made another market filing with the European...
Boston Scientific Posts Strong Q4 and Full-Year 2024 Results
Boston Scientific Corporation (NYSE: BSX) released its Q4 and full-year 2024 financial report, showing robust...
Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange
Suzhou-based Vigonvita Life Sciences Co., Ltd. has submitted an initial public offering (IPO) filing to...
NHSA Regulates DRG/DIP Payment Methods Under ‘1+3+N’ System
The National Healthcare Security Administration (NHSA) has released a set of regulations aimed at improving...
China’s NHSA and MoF Push for DRG/DIP Payment Reforms by 2025
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly released...
Sino Biopharmaceutical’s Tulobuterol Patch Gains NMPA Approval
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd...
Regeneron’s Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo
US-based biopharmaceutical company Regeneron (NASDAQ: REGN) released its Q4 2024 financial report, showing revenues up...